Sign In
Buy AYTU
$2.09
-0.0100 (-0.476%)
At Close: Jun 03, 2026
Aytu BioPharma to Participate in September 2022 Investor Conferences
08:00am, Wednesday, 24'th Aug 2022
ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare,
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
01:11pm, Tuesday, 19'th Apr 2022 PennyStocks
Here's what you need to know about trading penny stocks on April 19th
The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and I
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
09:11am, Tuesday, 19'th Apr 2022
Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and I
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
02:40pm, Friday, 18'th Feb 2022 Zacks Investment Research
Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
10:54am, Friday, 18'th Feb 2022
Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
01:38pm, Tuesday, 15'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage Bladder, Thyroid Cancer
Aytu BioScience GAAP EPS of -$0.44 beats by $0.14, revenue of $23.13M misses by $4.07M
10:16pm, Monday, 14'th Feb 2022 Seeking Alpha
Aytu BioScience press release (NASDAQ:AYTU): FQ2 GAAP EPS of -$0.44 beats by $0.14.Revenue of $23.13M (+52.7% Y/Y) misses by $4.07M.
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
04:38pm, Thursday, 09'th Dec 2021 Zacks Investment Research
The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
01:03pm, Thursday, 09'th Dec 2021
The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.
Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript
09:31pm, Monday, 15'th Nov 2021
Aytu Biopharma, Inc. (AYTU) CEO Josh Disbrow on Q1 2022 Results - Earnings Call Transcript
Aytu BioScience EPS misses by $0.60, misses on revenue
09:18pm, Monday, 15'th Nov 2021 Seeking Alpha
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
02:57pm, Sunday, 14'th Nov 2021 Benzinga
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Among the
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
08:05am, Monday, 08'th Nov 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, a
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
04:47pm, Thursday, 04'th Nov 2021
Aytu BioPharma Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
